<DOC>
	<DOCNO>NCT02490982</DOCNO>
	<brief_summary>The main goal investigator-initiated study evaluate effectiveness efficacy Teriflunomide population Relapsing Remitting Multiple Sclerosis ( RRMS ) patient treat regular practice , period least two year , regular set Multiple Sclerosis Clinic .</brief_summary>
	<brief_title>Teriflunomide Observational Effectiveness Study</brief_title>
	<detailed_description>Consenting adult RRMS patient , meet inclusion criterion prescribe Teriflunomide treat physician ask complete questionnaire quality life ( QoL ) , fatigue , employment . The study include 300 participant three Multiple Sclerosis ( MS ) Clinics . Disease magnetic resonance imaging ( MRI ) activity , blood test ( aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , complete blood count ( CBC ) ) , drug compliance , side effect , toxicity , monitor . MS patient never treat disease modifying drug ( DMD ) MS patient previously expose another DMD include . Some would single medication , others would treat two medication . The result study provide patient-perceived global impact Teriflunomide patient 's overall quality life . These result also guide physician give treatment adapt patient 's major concern .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Consenting Relapsing Remitting Multiple Sclerosis adult Expanded Disability Status Scale ( EDSS ) score â‰¤ 5.0 prescribe Teriflunomide agree follow study procedure . Primary progressive secondary progressive Multiple Sclerosis without relapse ; disease may confound evaluation outcome ; exclusion per product monograph ; woman contemplate pregnancy actually pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>